Q1 FY 2027 saw 59.1% revenue growth and strong margin expansion, driven by robust pharma intermediates and the launch of battery chemicals. Management reaffirmed 25% revenue growth guidance for FY 2027, with stable margins and continued investment in capacity and R&D.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.